Важливі досягнення в неврології за 2019 рік
DOI:
https://doi.org/10.30978/UNJ2020-1-57Посилання
Malyavin AG, Lobzhanidze FA, Tsiberkin AI, Kusevich DA, Bril' EV, Nikonov EL Itogigoda Samoeinteresnoeivazhnoe v meditsine v ukhodyashchem 2019-m Non nocere’. Novyiterapevticheskiizhurnal 2019;(12):16-35 [in Russian].
Al-Karagholi MA, Hansen JM, Guo S et al. Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 2019;142:2644-2654. doi: 10.1093/brain/awz199.
Alzheimer’s association. 2020 Alzheimer's disease facts and figures. Alzheimers and dement. 2020;16:391-460. doi: 10.1002/alz.12068..
Cortese I, Muranski P, Enose-Akahata Y et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380 (17):1597-1605. doi: 10.1056/NEJMoa1815039.
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi: 10.1016/S1474-4422 (18)30499-X.
Goadsby PJ, Dodick DW, Leone M et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132-141. doi: 10.1056/NEJMoa1813440.
Goadsby PJ, Wietecha LA, Dennehy EB et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894-1904. doi: 10.1093/brain/awz134.
Lipton RB, Croop R, Stock EG et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142-149. doi: 10.1056/NEJMoa1811090.
